McIver Zachariah
Chief Medical Officer
McIver Zachariah has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jan 2, 2026.
On the most recent filing, McIver Zachariah is listed as Chief Medical Officer at Janux Therapeutics, Inc. Inside the rolling window, McIver Zachariah reported no open-market purchases and 1 open-market sale totaling $37K in JANX.
Companies traded
Other insiders at JANX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$37K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has McIver Zachariah made?
McIver Zachariah has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does McIver Zachariah trade?
McIver Zachariah has filed SEC Form 4 disclosures for 1 company, including JANX.
When was McIver Zachariah's most recent SEC Form 4 filing?
McIver Zachariah's most recent SEC Form 4 filing on Tracefour is dated Jan 2, 2026.
What is McIver Zachariah's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, McIver Zachariah is listed as Chief Medical Officer.
What is McIver Zachariah's total buy and sell value in the current window?
Inside the rolling retention window, McIver Zachariah bought $0 and sold $37K based on SEC Form 4 filings.
What was McIver Zachariah's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,714 JANX shares on 2026-01-02, worth $37K, per SEC Form 4 filings.